Compare LSTA & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTA | DARE |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 24.0M |
| IPO Year | N/A | N/A |
| Metric | LSTA | DARE |
|---|---|---|
| Price | $2.05 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $23.50 | $10.00 |
| AVG Volume (30 Days) | ★ 139.2K | 94.7K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000.00 | N/A |
| Revenue This Year | N/A | $5,401.89 |
| Revenue Next Year | N/A | $6,257.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.81 | $1.61 |
| 52 Week High | $4.20 | $9.19 |
| Indicator | LSTA | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 44.75 |
| Support Level | $1.86 | $1.70 |
| Resistance Level | $2.13 | $1.84 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 53.76 | 47.50 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.